NEW DELHI: (Sep 11) Dr Reddy’s Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire Stugeron brand across the EMEA regions, with India and Vietnam as key markets.

Stugeron contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo.

The acquisition presents a strategic opportunity for the Hyderabad-based drug firm to expand its footprint in the anti-vertigo space as well as strengthen its Central Nervous System (CNS) portfolio, Dr Reddy’s Laboratories said in a statement.